摘要
目的评价培美曲塞联合奥沙利铂治疗老年或功能状态评分差的晚期肺腺癌的有效性和安全性。方法研究对象为未接受过一线化疗的老年或功能状态评分差的ⅢB/Ⅳ期肺腺癌患者,采用培美曲塞联合奥沙利铂方案,每3周为1个周期重复。连用2~6个周期评价疗效和不良反应,并进行随访。结果 39例患者中CR 2例(5.1%),PR6例(15.4%),SD15例(38.5%),PD16例(41.0%),RR20.5%,DCR59.0%,MST 9个月。主要毒副反应为I^II度骨髓抑制、神经毒性和胃肠道反应,经对症处理后不影响化疗进行。结论培美曲塞联合奥沙利铂方案治疗老年或功能状态评分差的晚期肺腺癌患者疗效肯定,不良反应轻。
Objective To observe the clinical efficacy and safety of pemetrexed combined with oxaliplatin on elderly patients or poor performance status patients with advanced lung adenocarcinoma. Methods The elderly patients or poor performance status patients with advanced lung adenocarcinoma （ⅢB/Ⅳstage） without receiving the first-line chemotherapy before were recruited in this study. They were treated with pemetrexed combined with oxaliplatin scheme, every 3 weeks for 1 course of treatment. The scheme was applied to the treatment of the patients for 2-6 courses, then the clinical efficacy and adverse reactions were evaluated and the patients were followed up. Results Among the 39 patients, 2 patients got complete response （5.1%）, 6 patients got partial response （15.4%）, 15 stable disease （38.5%）, and 16 progressive disease （41.0%）, The total response rate was 20.5%, and disease control rate was 59.0%, The median overall survival period were 9 months. The incidence of main toxicity were I^II degree bone marrow depression, neurological and gastrointestinal toxicity, which did not affect the chemotherapy after symptomatic treatment. Conclusion The regimen of pemetrexed combined with oxaliplatin has positive curative effect on elderly patients or poor perfor-mance status patients with advanced lung adenocarcinoma with milder adverse reactions.
出处
《中外医疗》
2014年第10期36-37,共2页
China & Foreign Medical Treatment
关键词
晚期肺腺癌
老年患者
功能状态评分差患者
培美曲塞
奥沙利铂
Advanced lung adenocarcinoma
Elderly patients
Patients with poor performance status
Pemetrexed
Oxaliplatin
